Page 16 - Read Online

Abughanimeh et al. J Cancer Metastasis Treat 2020;6:50 I http://dx.doi.org/10.20517/2394-4722.2020.110 Page 11 of 13

Reviewed, edited, and approved the final manuscript: Ernani V, Marr A, Ganti AK
Contributed to the manuscript: Abughanimeh O, Ernani V, Marr A, Ganti AK

Availability of data and materials
Not applicable.

Financial support and sponsorship
All authors have declared that they have no financial relationships at present that is related to this paper.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:
analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
3. Bunn PA Jr, Minna JD, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into
improved outcomes? J Thorac Oncol 2016;11:453-74.
4. Nakazawa K, Kurishima K, Tamura T, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett 2012;4:617-20.
5. Bernhardt EB, Jalal SI. Small cell lung cancer. In: Reckamp KL, editor. Lung Cancer. Cham: Springer International Publishing; 2016. pp.
301-22.
6. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J
Med 2018;379:2220-9.
7. Paz-ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-
stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39.
8. Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther 2017;180:16-23.
9. National Comprehensive Cancer Network. Small cell lung cancer. Version 3.2020. Available fron: https://www.nccn.org/professionals/
physician_gls/pdf/sclc.pdf [nccn.org]. [Last accessed on 04 Aug 2020 ].
10. Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, et al. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan
or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Future Oncol 2019;15:231-9.
11. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a
phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-6.
12. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of
recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67.
13. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in
patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
14. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell
lung cancer. J Clin Oncol 2007;25:2086-92.
15. Huber RM, Reck M, Gosse H, et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J
2006;27:1183-9.
16. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-
label, phase 2 basket trial. Lancet Oncol 2020;21:645-54.
17. Elez ME, Tabernero J, Geary D, et al. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
Clin Cancer Res 2014;20:2205-14.
18. Calvo E, Moreno V, Flynn M, et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: